202. Smith-Magenis syndrome
[
6 clinical trials,
6 drugs（DrugBank:
3 drugs),
2 target genes / 2 target pathways ]
Searched query = "Smith Magenis syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03492970 | March 7, 2018 | 6 May 2019 | Melatonin in Adults With SMS | Characterization of Behavioral Disorders and 24 H-melatonin Level in Adults With Smith Magenis Syndrome | Smith Magenis Syndrome | Biological: Hourly dosing of the nychtemeral secretion of melatonin | Hôpital le Vinatier | Hospices Civils de Lyon | Not recruiting | 18 Years | 65 Years | All | 10 | N/A | France |
| 2 | NCT03013543 | January 2017 | 30 September 2019 | Setmelanotide Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity | Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity | Pro-opiomelanocortin (POMC) Deficiency Obesity (Heterozygous or Epigenetic);Leptin Receptor Deficiency Obesity;Bardet-Biedl Syndrome;Alstrom Syndrome;Smith-Magenis Syndrome | Drug: Setmelanotide | Rhythm Pharmaceuticals, Inc. | Recruiting | 12 Years | N/A | All | 80 | Phase 2/Phase 3 | United States;Spain;United Kingdom | |
| 3 | NCT02776215 | September 2016 | 16 December 2017 | Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents | Open-label Study to Investigate the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents | Circadian Rhythm Sleep Disorders;Non-24 Hour Sleep-Wake Disorder;Autism Spectrum Disorder;Smith-Magenis Syndrome | Drug: tasimelteon | Vanda Pharmaceuticals | Recruiting | 3 Years | 17 Years | All | 24 | Phase 1 | United States | |
| 4 | NCT02231008 | September 2015 | 23 May 2016 | Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS | Smith-Magenis Syndrome;Circadian | Drug: tasimelteon | Vanda Pharmaceuticals | Recruiting | 16 Years | 65 Years | Both | 48 | Phase 2/Phase 3 | United States | ||
| 5 | NCT00506259 | July 17, 2007 | 11 November 2019 | Treatment Strategies for Children With Smith-Magenis Syndrome | A Phase One Treatment Trial of the Circadian Sleep Disturbance in Smith-Magenis Syndrome (SMS) | Developmental Delay Disorders;Chromosome Deletion;Mental Retardation;Sleep Disorders, Circadian Rhythm;Self Injurious Behavior | Drug: dTR Melatonin (NIH CC PDS);Device: Phototherapy (Bright Light);Drug: Melatonin CR | National Human Genome Research Institute (NHGRI) | Not recruiting | 3 Years | 45 Years | All | 23 | Phase 1 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT00691574 | September 1998 | 19 February 2015 | Melatonin Levels in Smith Magenis Syndrome (SMS) | Melatonin Levels in Sleep-disordered Smith-Magenis Syndrome: a Pilot Study | Chromosome Disorders | Dietary Supplement: Melatonin;Device: Enviro-light artificial light box | Oregon Health and Science University | Not recruiting | 3 Years | 85 Years | Both | 5 | N/A | United States |